Smith & Nephew stock trades near its yearly low

Smith & Nephew stock stood at GBp 1,004.25 in London trading on September 24, 2026, just GBp 3.25 above its 52-week low of GBp 1,001.00. The medical technology group had launched its EVOS PELVIC Plating System in the United States one day earlier, adding a concrete product catalyst to a share price near the bottom of its yearly range.

New pelvic system reaches US

According to Smith+Nephew in its September 23, 2026 release, the all-in-one system combines plates, cannulated screws and specialized instruments for pelvic and acetabular fracture surgery. The system is currently available in the United States and was presented at the 2026 Orthopaedic Trauma Association meeting in Nashville.

The launch extends the company's EVOS platform into a new fracture-management application. For investors, the commercial relevance depends on how quickly the new system broadens the trauma and extremities portfolio, especially while recent growth has been modest in some core markets.

Profit growth outpaces revenue

Smith & Nephew reported first-half 2026 revenue of USD 3.10 billion, up from USD 2.961 billion in the comparable period, while operating profit increased to USD 448 million from USD 429 million, according to MetaTrader.

The comparison shows the key operating signal: revenue grew 4.6 percent on a reported basis, while trading profit rose 8.1 percent to USD 566 million. The trading profit margin expanded to 18.3 percent from 17.7 percent, and adjusted earnings per share increased to 35.6 cents from 33.5 cents in the first half of 2025.

Stock stays near yearly low

Smith & Nephew stock was 0.32 percent lower on September 24, 2026, at GBp 1,004.25 on the London market. Its 52-week range of GBp 1,001.00 to GBp 1,426.50 places the latest quote 29.6 percent below the yearly high, making operating execution and product adoption important reference points for the valuation.